4.6 Letter

Third doses of SARS-CoV-2 vaccines in immunosuppressed patients with inflammatory bowel disease

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Gastroenterology & Hepatology

Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD

Nicholas A. Kennedy et al.

Summary: Infliximab treatment in patients with inflammatory bowel disease results in attenuated serological responses to a single dose of the SARS-CoV-2 vaccine. Delayed second dosing should be avoided in these patients, as vaccination after SARS-CoV-2 infection or a second dose leads to seroconversion in most individuals.
Article Gastroenterology & Hepatology

Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: A prospective study

Gionata Fiorino et al.

INFLAMMATORY BOWEL DISEASES (2012)